Eric Topol

they, of course, it wasn't getting any stimulation.

It was just the device was in.

That's the ultimate control in a device randomized trial, right?

That's impressive.

Now, one of the people was asking, what's the name of the device?

I mean, it's a VNS, a vagal nerve stimulator.

Is there a name to this?

Amazing, really.

One minute a day.

Now, why don't we have for all autoimmune diseases, why isn't this become a frontline therapy instead of all the drugs?

Yeah.

That much, actually.

Well, I think the autoimmune diseases that you just touched on, I mean, they all deserve study.

The rheumatoid arthritis results are so striking that in refractory people, no less potentially to avoid immunosuppression and all these other side effects, it has a lot of potential.

Now, one of the questions that one of the listeners brought up

was about an external device.

And that brings me to long COVID.

So POTS, as you know very well, postural orthostatic tachycardia syndrome, very prominent among people with long COVID.

Along the way, there was a company in Canada that was an external vagal nerve stimulator.

Has this been tested?